FEATURES OF THE COURSE OF COVID-19 INFECTION IN ONCOLOGICALPATIENTS

Authors (1)

Abstract

According to the World Health Organization (WHO), more than 14.1 million new cancer cases (excluding non-melanoma skin cancer) and approximately 8.2 million cancer-related deaths (about 22,000 deaths per day) were recorded worldwide in 2012 [5]. Fifty-seven percent of cancer cases (8 million) and 65.0% of deaths (5.3 million) occurred in developing countries, where approximately 82% of the world’s population resides [4]. Globally, one out of every seven deaths is caused by cancer, exceeding the combined mortality from AIDS, tuberculosis, and malaria. Malignant neoplasms (25%) represent the second leading cause of death after cardiovascular diseases (38%) in high-income countries, and rank third (12%) after cardiovascular (30%) and infectious and parasitic diseases (14%) in low- and middle income countries [1]. It is projected that by 2030, due to population growth and aging, the number of new cancer cases will reach 21.7 million, with approximately 13 million deaths. In addition to human losses, the economic burden is substantial. Direct and indirect costs are estimated at hundreds of billions of dollars annually [2], and these figures are expected to increase in the future due to the rising incidence of cancer and the growing cost of treatment [3].

Keywords

Cite this article

References

1. [1]Abdelhady A. COVID-19-associated sleep disorders: A case report // Neurobiol Sleep Circadian Rhythms. 2020. Vol.
2. [2]– Р. 21-37.
3. [3]Ahn E., Araki K., Hashimoto M., Li W., Riley J.L., Cheung J., Sharpe A.H., Freeman, G.J., Irving, B.A., Ahmed, R. Role of PD-1 during effector CD8 T cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 2018.115. – Р. 4749-4754.
4. [4]Akalin E, Azzi Y, Bartash R. Covid-19 and kidney transplantation // N Engl J Med. 2020;382. – Р.2475-2477.
5. [5]Andersson E. Brief online-delivered cognitive-behavioural therapy for dysfunctional worry related to the covid-19 pandemic: A randomised trial // PsyArXiv. 2020.- №
6. [6]– Р. 10-21.
7. [7]Arabi, Y.M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K. Ribavirin and Interferon Therapy for 41 Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study // Clin. Infect. Dis. 2020.70. – Р. 1837-1844.
8. [8]Asmundson G.J., Taylor S. Coronaphobia: Fear and the 2019-nCoV outbreak // Journal of Anxiety Disorders. 2020. Vol.
9. [9]– Р.1-19.
10. [10]Baden LR, El Sahly HM, Essink B. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine // N Engl J Med. 2021;384(5). – Р.403–416.
11. [11]Baruah V., Bose, S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV// J. Med. Virol. 2020.92. – Р. 495-500.
12. [12]Barrett JR, Belij-Rammerstorfer S, Dold C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses // Nat Med. 2021;27 (2): – Р.279–288.
13. [13]Адамян Л.В., Азнаурова Я.Б.,Филлипов О.С. Проблемы репродукции COVID-19 и здоровье // Журнал Эпидемиология и инфекционные болезни. – М., 2020. №
14. [14]– С. 6-17.
15. [15]Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu, Zhenshun Cheng, Ting Yu, Jiaan Xia, Yuan Wei, Wenjuan Wu, Xuelei Xie, Wen Yin, Hui Li, Min Liu, Yan Xiao, Hong Gao, Li Guo, Jungang Xie, Guangfa Wang, Rongmeng Jiang, Zhancheng Gao, Qi Jin, Jianwei Wang, Bin Cao. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // The Lancet. 2020; 395(10223). – Р.497-506.
16. [16]Channappanavar, R., Fehr, A.R., Zheng, J., Wohlford-Lenane, C., Abrahante, J.E., Mack, M., Sompallae, R., McCray, P.B., Meyerholz, D.K., Perlman, S. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes // J. Clin. Invest. 2019.129. – Р.3625-3639.
17. [17]Charbonneau, M.R., Isabella, V.M., Li, N., Kurtz, C.B. Developing a new class of engineered live bacterial therapeutics to treat human diseases // Nat. Commun. 2020.11. – Р. 1738-1738.